Abbas Hussain Biography and Net Worth

Director of Moderna

Mr. Hussain most recently served as Chief Executive Officer of Vifor Pharma from 2021 to 2023. Prior to that, he served in various leadership roles at GlaxoSmithKline, most recently as global president, pharmaceuticals & vaccines. Earlier in his career, Mr. Hussain held various global leadership roles at Eli Lilly and Company.

Mr. Hussain currently holds various non-executive director and advisory roles, including as the Chairman of Asceneuron SA, director for Mallinckrodt Pharmaceuticals and Alfasigma SpA and as an advisor to 4Bio Capital. He previously served on the boards of Cochlear Limited, CSL, Teva Pharmaceutical and Immunocore.

Mr. Hussain holds a BSc from the Loughborough Institute of Technology.

What is Abbas Hussain's net worth?: The estimated net worth of Abbas Hussain is at least $51.27 thousand as of December 9th, 2025. Hussain owns 1,515 shares of Moderna stock worth more than $51,268 as of January 12th. This net worth approximation does not reflect any other investments that Hussain may own. Learn More about Abbas Hussain's net worth.
How do I contact Abbas Hussain?: The corporate mailing address for Hussain and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Abbas Hussain's contact information.
Has Abbas Hussain been buying or selling shares of Moderna?: Abbas Hussain has not been actively trading shares of Moderna during the past quarter. Most recently, Abbas Hussain sold 504 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.60, for a transaction totalling $13,910.40. Following the completion of the sale, the director now directly owns 1,515 shares of the company's stock, valued at $41,814. Learn More on Abbas Hussain's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (Chief Executive Officer), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Abbas Hussain (Director), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 2 times. They sold a total of 24,357 shares worth more than $717,096.84. The most recent insider tranaction occured on December, 11th when Director Noubar Afeyan sold 23,853 shares worth more than $703,186.44. Insiders at Moderna own 10.9% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 12/11/2025.

Abbas Hussain Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/9/2025	Sell	504	$27.60	$13,910.40	1,515

Abbas Hussain Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $33.84

$32.37

$34.66

50 Day Range

MA: $28.31

$22.36

$35.89

2 Week Range

Now: $33.84

$22.28

$45.40

Volume

9,432,541 shs

Average Volume

11,480,480 shs

Market Capitalization

$13.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17